| Literature DB >> 32316332 |
Kristine Salmina1, Agnieszka Bojko2, Inna Inashkina1, Karolina Staniak2, Magdalena Dudkowska2, Petar Podlesniy3, Felikss Rumnieks1,4, Ninel M Vainshelbaum1,4, Dace Pjanova1, Ewa Sikora2, Jekaterina Erenpreisa1.
Abstract
Mitotic slippage (MS), the incomplete mitosis that results in a doubled genome in interphase, is a typical response of TP53-mutant tumors resistant to genotoxic therapy. These polyploidized cells display premature senescence and sort the damaged DNA into the cytoplasm. In this study, we explored MS in the MDA-MB-231 cell line treated with doxorubicin (DOX). We found selective release into the cytoplasm of telomere fragments enriched in telomerase reverse transcriptase (hTERT), telomere capping protein TRF2, and DNA double-strand breaks marked by γH2AX, in association with ubiquitin-binding protein SQSTM1/p62. This occurs along with the alternative lengthening of telomeres (ALT) and DNA repair by homologous recombination (HR) in the nuclear promyelocytic leukemia (PML) bodies. The cells in repeated MS cycles activate meiotic genes and display holocentric chromosomes characteristic for inverted meiosis (IM). These giant cells acquire an amoeboid phenotype and finally bud the depolyploidized progeny, restarting the mitotic cycling. We suggest the reversible conversion of the telomerase-driven telomere maintenance into ALT coupled with IM at the sub-telomere breakage sites introduced by meiotic nuclease SPO11. All three MS mechanisms converging at telomeres recapitulate the amoeba-like agamic life-cycle, decreasing the mutagenic load and enabling the recovery of recombined, reduced progeny for return into the mitotic cycle.Entities:
Keywords: ALT; SQSTM1/p62; amoeboid conversion; budding of mitotic progeny; cellular senescence; extranuclear DNA; genotoxic treatment; inverted meiosis; mtTP53 cancer; polyploidization
Year: 2020 PMID: 32316332 PMCID: PMC7215480 DOI: 10.3390/ijms21082779
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1MDA-MB-231 cell culture (grown for 24 h in chamber slides), untreated and in the course of recovery after doxorubicin (DOX) treatment: (A,B) untreated control (arrows, mobile cells in epithelial–mesenchymal transition (EMT); * 8C; ** a multinuclear cell); (C–E) giant amoeboid cells on Day 13 post-DOX treatment budding spore-like subcells, which are extremely enriched in actin and tubulin; and (F–H) seven-week cell culture explanted from the escaped clone on Day 19 after DOX treatment. (F) A giant multinuclear cell is budding two subcells (arrows); the bi-polar ana-telophase on the right is spinning one daughter by the actin structure twisting around a spindle. (G) From the same culture, the progeny in a tripolar division (arrow) is situated on the giant cell. (H) View of the escaped clone with a general phenotype similar to the non-treated control. Bars = 25 µm.
Figure 2The quantified parameters of MDA-MB-231 cells following DOX treatment: (A) the cell growth curves of three independent experiments with a mean (a dashed line); (B) the reciprocal relationship between mitotic (2C) and polyploid (>4C) cell numbers overtime for three independent experiments (with SD); (C) representative differential mitotic counts (from Experiment 3, shown in (A) by the green line); (D) viability test with trypan blue from Experiment 3 (green curve in (A) and in (C)); (E) results of gene transcription evaluation obtained by Selfie digital PCR for three gene transcripts quantified per gene copy and per cell (as transcripts per gene copy multiplied by the average ploidy in the same experiment)—the average of three technical replicates with SEM; and (F) the dynamics of the senescence marker Sa-β-gal and proliferation marker Ki-67 along with DNA double-strand breaks (γH2AX) in three independent experiments and their repair by homologous recombination—cells with colocalized Rad51/γH2AX foci. (ANOVA with post hoc analysis (Tukey’s HSD test), *** p < 0.001.
Figure 3Representative cell cycle changes monitored with in situ DNA cytometry in the dynamics of the DOX treatment experiment: (Left) DNA histograms of interphase cell nuclei; and (Right) the DNA content in mitosis. Interruption of normal mitoses (Days 4–16) coincides with polyploidizing cycles. Bifurcation for depolyploidizing and continuing polyploidization sublines on Day 16 precedes resumption of the normal mitotic cycle on Day 18.
Figure 4Characterization of aberrant mitosis and mitotic slippage (MS) by several in situ methods applied post-DOX treatment. Representative pictures from three or more experiments for each issue. (A–C) Aberrant metaphases with loopy chromosomes ((A,B) arrows) and their fragments, some circular ((B) arrowhead). (A) DOX-D4. (insert: normal anaphase of the non-treated (NT) control). (B,C) DNA staining with Toluidine blue (DOX-D16 and D18) (insert: normal 4C metaphase of NT). (D–K) Mitotic slippage: (D) defects of the lamina in the main nucleus and most cytoplasmic DNA clumps (DOX-D11); (E) holokinetic arrangement of kinetochores in the main nucleus and release of the damaged DNA into the cytoplasm (DOX-D5) (insert: metaphase of NT); (F) Fluorescence In Situ Hybridization (FISH) with the telomere and cen#2 probes showing retention of centromeres in the cell nucleus and release of a proportion of telomeres into the cytoplasm (DOX-D4) (insert: normal metaphase of NT); (G) preferential release of the telomere shelterin-TRF2-associated chromatin into the cytoplasm (DOX-D7) (insert: normal metaphase of NT); (H) the lamina-associated heterochromatin mark H3K27me3 (DOX-D5) showing partial release into the cytoplasm (insert: normal mitosis of NT with preferential localization of H3K27me3 mark on telomere ends); (I,J) early MS (yet pH3ser10-positive) with finely fragmented cytoplasmic DNA is surrounded by the LAMP2-positive lysosomal material (DOX-D7); (K,L) two cells in MS stained with 4′,6-diamidino-2-phenylindole (DAPI) for DNA and positively for Sa-β-gal (DOX-D4); and (M) a giant cell with senescence marks: DNA DSBs in cell nuclei and enrichment of cytoplasm with secreted (arrow) Interleukin-6 (IL6) (DOX-D8). Bars = 10 µm.
The dynamics of the cell cycle and MS after DOX treatment.
| Sample | Average Ploidy * | Normal Cycle | Aberrant Metaphase | Mitotic Slippage | Polyploidy Cycles | Hyperploidy > 20C | Normal Mitosis |
|---|---|---|---|---|---|---|---|
| Day 0 | 2.68C | + | − | − | − | − | + |
| Day 4 | 3.65C | − 1 | ++ | + | + | − | − |
| Day 8 | 7.47C | − | + | ++ | +++ | + | − |
| Day 16 | 12.15C | +/− | +/− | +++ | ++ | +++ | - |
| Day 18 | 8.87C | + | − | + | + | ++ | + |
| Day 25 | 3.26C | + | − | − | − | −/+ | ++ |
* For the experiment presented on Figure 3; 1 severe DNA under-replication.
Figure 5Representative pictures of DNA repair of telomere DNA double-strand breaks by RAD51-dependent homologous recombination (HR) involving promyelocytic leukemia (PML) bodies, a sign of alternative lengthening of telomeres (ALT) in giant post-DOX cell nuclei undergoing MS cycles with sorting the damage signaling DNA out into the cytoplasm and reconstituting subnuclei free of it: (A–D) Days 5–8 post-DOX (n = 3). The typical HR configurations are boxed, the extranuclear damaged DNA on (D) arrowed. (E,F) Reconstitution of subnuclei in two similar cells (DOX-D8-9): (E) the extranuclear damaged DNA (arrowed) does not contain PML bodies; and (F) FISH with the telomere and cen#2 probes (n = 3) showing the telomere label cluster in the extranuclear DNA (arrowed). (G–I) The release of four repaired subnuclei (boxed) from a defect in the giant mother nucleus (reconstructed in J); high Ki-67 positivity of the sorted DNA signaling damage by γH2AX-label on DOX-D19 (n = 3). Bars = 10 µm.
Figure 6(A–F) The release of the TERT-TRF2-γH2AX-marked chromatin into the cytoplasm of DOX-treated cells (DOX-Days 5–8, if not specified otherwise; n ≥ 3) accompanied by the autophagy adaptor SQSTM1/p62: (A) TERT-positive metaphase in NT control (DNA counterstained by propidium iodide); (B) separation of the TERT-enriched circular fragments (arrows) in the restituting polyploid metaphase (insert: a chromosome doublet ending by two circular structures); (C) mitotic slippage with TERT-enriched cytoplasmic DNA, poor in the nucleus (DOX-Day 5); (D) the conventional TERT-positivity in the escape telophase cell (DOX-Day 22); (E) a giant cell after MS surrounded by clumps of extranuclear DNA enriched with TRF2 (insert: the TRF2-positive telophase of the NT); (F) a fragment of the giant MS cell with two boxed chromatin TRF2-enriched fragments marked by DNA damage (γH2AX) in the cytoplasm; (G) the giant MS cell with abundant extranuclear chromatin enriched with TRF2 and attached SQSTM1/62 protein using RGB filter (the green channel was removed) (insert: from the boxed fragment, the blue channel is removed); (H) the bi-nuclear giant cell with RAD51 repair foci that are apart from the cluster of p62 foci; (I) p62 is scarce in the nuclei of NT cells; (J) nuclear clustering of p62 foci in a giant DOX-treated cell; (K) enlarged nuclear fragment boxed in (J) with removed blue DAPI channel reveals the attachment of TRF2 foci to the p62 clusters; (L) an octoploid cell with several p62 nuclear foci surrounded by TRF2 and a cytoplasmic chromatin fragment, shown enlarged in the insert without the blue channel with clear colocalization of TRF2 and p62; (M) cytoplasmic fragments of the MS cell co-stained for p62, LAMP2, and DNA showing accumulation of p62 in the membrane of lysosomal vesicles, perhaps attracting cytoplasmic DNA to them; and (N) the giant cell in the terminal senescence with typical nuclear polymorphic enlarged PML bodies accumulating p62 (enlarged on the insert). Bars = 10 µm.
Figure 7Expression of the meiotic genes and proteins after DOX treatment. (A) RT-PCR results of gene transcription are shown in folds. Representative charts of two independent experiments, with three technical replicates; (B) MOS protein induction on Days 4 and 9 after DOX treatment, analyzed by Western Blot in four independent experiments. (C) The protein level of MOS; densitometry analysis of Western blot bands (n = 4) (the p-value is stated as: * 0.01 < p < 0.05; ** 0.001 < p < 0.01); # statistical significance between subsequent days of DOX treatment.
Figure 8Expression of meiotic and germline proteins in MS and giant cells found by Immunofluorescence—representative images for at least three experiments: (A) a tetraploid cell nucleus enriched with MOS-kinase (sc-86) colocalized and juxtaposed with CYCLIN B1 (DOX-D2); (B) an attachment of MOS to the centrosomes and microtubules of the tripolar mitosis (DOX-D4); (C) MOS and α-TUBULIN form a monopolar spindle in the early prophase (DOX-D4); (D) MOS is attached to interphase centrosomes (arrow) and shows a remnant of a monopolar spindle in MS (asterisk) [12]; (E) the restituting nucleus in MS becomes poor with MOS and CYCLIN B1 (DOX-D4); (F–H) a giant cell in MS releasing cytoplasmic DNA shows the enrichment of the cell nucleus with DMC1 (meiotic recombinase) and REC8 (meiotic cohesin) (DOX-D19); (I) REC8 grains are scarcely inserted in the kinetochore chains in the MS cell (arrow) (DOX-D4); (J) DMC1 grains are scarcely inserted in the MS cell (DOX-D7; [12]); (K) a giant cell enriched with OCT4A in the cell nucleus (a monoclonal Ab) and OCT4B in the cytoplasm (DOX-D5); and (L) a giant cell enriched with the germ markers, DDX4/VASA in the cell nucleus and FRAGILIS in the cytoplasm (DOX-D7). Bars = 10 µm.
Figure 9A schematic showing the cytoplasmic sorting of hTERT/TRF2-marked DNA damage signaling telomere ends cut off by a telomere break during mitotic slippage. This process is associated with the ALT-RAD51-driven repair by homologous recombination of the two co-aligned trimmed telomeres occurring in specific nuclear PML (APB) bodies. ALT may be coupled with inverted meiosis (IM) by recombining homologous chromosomes conjugated by telomeres at the same breakage site. In this case, the breakage sites can be introduced by meiotic nuclease SPO11. The ubiquitination protein SQSTM1/62 participates in the sorting of the extranuclear DNA.
The antibodies used, their specificity, and source.
| Antibody Against | Description | Specificity/Immunogen | Used Concentration | Product No. and Manufacturer |
|---|---|---|---|---|
| AURORA B | Rabbit polyclonal | A peptide derived from within residues 1–100 of human Aurora B | 1:300 | ab2254, Abcam, Cambrige, UK |
| BrdU | Mouse monoclonal | Recognizes the thymidine analog 5-bromo-2′-deoxyuridine (BrdU) | 1:100 | A21300, Invitrogen, Carlsbad, CA, USA |
| α-Tubulin | Mouse monoclonal | Recognizes an epitope located at the C-terminal end of the α-tubulin isoform in a variety of organisms | 1:1000 | T5168, Sigma-Aldrich, St. Louis, MO, USA |
| Centromere protein | Human | Derived from human CREST patient serum | 1:50 | 15–234, Antibodies Inc., Davis, CA, USA |
| CYCLIN B1 | Mouse monoclonal | Raised against a recombinant protein corresponding to human cyclin B1 | 1:100 | sc-245, Santa Cruz, Dallas, TX, USA |
| DMC1 | Mouse monoclonal | Specific for DMC1, does not cross-react with the related protein Rad51 | 1:100 | ab11054, Abcam, Cambridge, UK |
| F-ACTIN | Phalloidin-iFlour 594 Conjugate | 1:500 | ab176757, Abcam, Cambridge, UK | |
| FRAGILIS | Rabbit polyclonal | The details of the immunogen for this antibody are not available | 1:50 | ab65183-100, Abcam, Cambridge, UK |
| GAPDH | Mouse monoclonal | Raised against recombinant GAPDH of human origin | 1:50000 | sc-47724, Santa Cruz, Dallas, TX, USA |
| IL6 | Rabbit polyclonal | Synthetic peptide | 1:50 | orb87798, Biorbyt, Cambridge, UK |
| γ-H2AX | Rabbit polyclonal | Recognizes mammalian, | 1:200 | 4411-PC-100, Trevigen, Gaithersburg, MD, USA |
| γ-H2AX | Mouse monoclonal | Synthetic peptide sequence surrounding phosphorylated Ser140 | 1:200 | Ma1-2022, Pierce, Waltham, MA, USA |
| H3K27me3 | Rabbit polyclonal | Synthetic peptide within human Histone H3 aa 1–100 | 1:200 | ab6147, Abcam, Cambridge, UK |
| Ki67 | Rabbit polyclonal | Synthetic peptide from C-terminus of human Ki-67 | 1:50 | PA5-16785, Pierce, Waltham, MA, USA |
| LAMIN B1 | Rabbit polyclonal | Peptide mapping at the C-terminus of Lamin B1 of human origin | 1:200 | ab1604, Abcam, Cambridge, UK |
| LAMP2 | Mouse monoclonal | The details of the immunogen for this antibody are not available | 1:500 | 555803, BD Pharmingen™, Franklin Lakes, NJ, USA |
| MOS (C237) | Rabbit polyclonal | Epitope mapping at the C-terminus | 1:50 | sc-86, Santa Cruz, Dallas, TX, USA |
| MOS | Rabbit polyclonal | Synthetic peptide corresponding to a region within internal sequence amino acids 107–156 | 1:500 | Ab99017, Abcam, Cambridge, UK |
| OCT 3/4 | Mouse monoclonal | Peptide raised against amino acids 1–134 of Oct-3/4 of human origin non-cross-reactive with Oct-3/4 isoforms B and B1 | 1:50 | sc-5279, Santa Cruz, Dallas, TX, USA |
| OCT4 | Rabbit polyclonal | A peptide derived from within residues 300 to the C-terminus of human Oct4 | 1:200 | ab19857, Abcam, Cambridge, UK |
| Rabbit polyclonal | Epitope corresponding to phosphorylated Thr172 of AMPKα1 of human origin | 1:50 | sc-101630, Santa Cruz, Dallas, TX, USA | |
| pH3Ser10 | Mouse monoclonal | Recognizes Phospho- S10 on Histone H3 | 1:200 | ab14955, Abcam, Cambridge, UK |
| PML | Mouse monoclonal | Epitope corresponding to amino acids 37–51 mapping near the N-terminal of PML of human origin | 1:200 | sc-966, Santa Cruz, Dallas, TX, USA |
| P62/SQSTM1 | Rabbit polyclonal | A synthetic peptide corresponding to Human SQSTM1/ p62 (C-terminal) | 1:200 | ab91526, Abcam, Cambridge, UK |
| RAD51 | Mouse monoclonal | Recombinant full-length protein corresponding to human Rad51 aa 1–338 | 1:50 | ab213, Abcam, Cambridge, UK |
| REC8 | Rabbit polyclonal | Peptide mapping near the N-terminus of Rec8 of human origin | 1:50 | 10793-1-AP, Proteintech Group, Manchester, UK |
| TERT | Mouse monoclonal | Recombinant full-length protein (human) from insect cells | 1:50 | ab5181, Abcam, Cambridge, UK |
| TRF2 | Mouse monoclonal | His-tagged, fusion protein, corresponding to full-length TRF2 (Telomeric Repeat binding Factor 2) | 1:100 | 05-521, Millipore, Temecula, CA, USA |
| VASA/DDX4 | Mouse monoclonal | A synthetic peptide corresponding to residues near the N-terminus of human DDX4 | 1:50 | MA5-15565, Pierce, Waltham, MA, USA |
| 5-Methylcytosine | Mouse monoclonal | Detects methylated DNA or RNA | 1:200 | NA81, Calbiochem, Merck, Burlington, MA, USA |
The primers applied in RT-PCR for POU5F1 and meiotic proteins.
| Gene | Forward Primer Sequence | Reverse Primer Sequence | Amplicon Length | Tann (°C) | Reference | Sequence ID |
|---|---|---|---|---|---|---|
|
| TCGCAAGCCCTCATTTCACC | GCCAGGTCCGAGGATCAAC | 157 | 56 | [ | NM_002701.5 |
|
| AGACTATTCCTTGGGGCCACAC | GGCTGAATACCTTCCCAAATAGA | 244 | 58 | [ | NM_203289.5 |
|
| TGACCGCATCTCCCCTCTAA | AGCTTACCACCTCTTCCCAG | 134 | 58 | [ | NM_001285986.1 |
|
| CGGTGTTCCTGTGGCCATAA | GCAGGCCGTTCACAACATC | 250 | 58 | [ | NM_005372.1 |
|
| TGAGGGTGAATGTGGTGAAA | CTGGGATTGCAGCCTCTAAG | 400 | 56 | [ | NM_005132.2 |
|
| AGCAGCAAAGTTCCATGAAG | TGAGCTCTCCTCTTCCCTTT | 300 | 54 | [ | NM_007068.3 |
|
| TGAGGTTCTTGCATCTATAGAAA | AAATTTTTGAGCTGATTTTGGTG | 240 | 58 | in house | NM_012444.2 |
|
| AGTGTGACGTGGACATCCG | AATCTCATCTTGTTTTCTGCGC | 349 | 56 | [ | NA |
The primers used for selfie-digital PCR.
| Gene Symbol | Amplicon Size | Forward Primer Sequence 5′-3′ | Reverse Primer Sequence 5′-3′ |
|---|---|---|---|
|
| 75 bp. | AAACCGGTGAATCTGGGCTT | CGGATAGGATAGGGGGCGTA |
|
| 97 bp. | GAGTAGTCCCTTCGCAAGCC | GAGAAGGCGAAATCCGAAGC |
|
| 95 bp. | TGTTGAACCAATGCTTTCTCATGT | CTCAGGCTGGCTTGTGAAGG |